Hester Biosciences acquires tech to develop Brucella vaccine from IVRI

Hester Biosciences informed the bourses on Wednesday that it has signed an agreement towards receiving the indigenously developed technology from Indian Council of Agriculture Research-Indian Veterinary Research Institute (ICAR-IVRI), for developing Brucella Abortus S19 Delta per vaccine.

The Government of India has planned to immunise 4 crore female calves in India in the first phase against Brucella through vaccination and in this regard, the company has committed to remain a part of the Government of India’s immunisation program.

While Hester is currently manufacturing the conventional Brucella Abortus S19 vaccine and supplying to all the states of India, the S19 Delta per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced safety, immunogenicity, as well as assuring lifelong immunity with a single shot in calf-hood.

With this vaccine, Hester hopes to reach new heights not only within India but also become a channel for immunising cattle against Brucella, worldwide. Hester aims to launch the Brucella Abortus S19 Delta per vaccine in 18 months.

Hester Biosciences is engaged in the manufacturing of poultry & large animal vaccines as well as in trading of poultry health products and large animal health products.

On Wednesday, the stock of Hester Biosciences closed at Rs 1,721.15 per share, up by 0.62 per cent or Rs 10.65 per share on BSE, against a 0.17 per cent decline in the benchmark index. The 52-week high is recorded at Rs 2,044.40 and the 52-week low is Rs 870 on BSE.